secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001104659-22-115418
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Q3 net loss $23.2M; KORSUVA revenue $16.2M, 180K vials shipped
-------------------------------------------------------------------

- Net loss $23.2M ($0.43/share) vs $1.0M loss ($0.02) in Q3 2021; total revenue $10.8M down from $20.3M.
- KORSUVA injection net sales $16.2M incl. $7.4M profit-share from Vifor; ~180K vials shipped to dialysis centers.
- Discontinued Phase 2 PBC trial due to slow enrollment; FDA meeting in 4Q22 to discuss NP pivotal program.
- Cash $179.5M at Sept 30, 2022 (Dec 2021: $236.8M); expects to fund ops into first half 2024.
- Appointed Ryan Maynard as CFO and Lisa von Moltke to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465922115418/0001104659-22-115418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465922115418/tm2229821d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer